To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Adding Liposomal Bupivacaine to Bupivacaine in Interscalene Blocks in Total Shoulder Arthroplasty

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
March 2023

Adding Liposomal Bupivacaine to Bupivacaine in Interscalene Blocks in Total Shoulder Arthroplasty

Vol: 303| Issue: 3| Number:28| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Comparing bupivacaine alone to liposomal bupivacaine plus bupivacaine in interscalene blocks for total shoulder arthroplasty: a randomized, non-inferiority trial.

Reg Anesth Pain Med. 2023 Jan;48(1): 1-6.

Contributing Authors:
DA Elmer JR Coleman CM Renwick PE Amato BC Werner SF Brockmeier AE Slee NA Hanson

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Eighty patients undergoing total shoulder arthroplasty were included in this non-inferiority trial assessing the non-inferiority of bupivacaine (n=40) vs. liposomal bupivacaine plus bupivacaine (n=40) in interscalene brachial plexus block. The primary outcome of interest was 72-hour opioid consumption. Secondary outcomes of interest included opioid consumption, pain scores at rest, during activity...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue